Kynurenine upregulate immune checkpoint expression and promote TEX in CRC via upregulating TOX expression, while IDO1 inhibitors and TOX knockdown can restore the anti-tumor activity of CD8+ T cells (138). The gene discussed is CD8A; the disease is colorectal carcinoma.